ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025
Immunosuppressant heterogeneity and outcomes in total joint arthroplasty: a comparative cohort study.
Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the widespread success of total joint arthroplasty (TJA), the impact of chronic immunosuppressant therapy on TJA outcomes remains unclear. This study aimed to evaluate the heterogeneous effects of various immunosuppressants on major postoperative complications in patients undergoing TJA.
methodsWe conducted a retrospective cohort study using the 2022 National Surgical Quality Improvement Program, which included 114,498 patients with TJA. Patients were categorized based on immunosuppressant use, including anti-rejection drugs, biological disease-modifying antirheumatic drugs (DMARDs), corticosteroids, synthetic DMARDs, and combination therapies. Major postoperative complications, such as cerebrovascular accident, cardiac arrest, myocardial infarction, septic shock, sepsis, pulmonary embolism, deep vein thrombosis, organ/deep space surgical site infection, return to the operating room, and readmission, were treated as a composite variable. Adjusted odds ratios (aOR) with 95% confidence intervals (CI) were calculated using multivariable logistic regression to assess the risk of major complications associated with each immunosuppressant category compared to non-immunosuppressant users.
resultsOf 114,498 TJA patients, 5,018 (4.4%) were receiving chronic immunosuppressant therapy. The incidence of major complications was higher among immunosuppressant users compared with non-users (10.44% vs 6.37%). Multivariable analysis revealed significantly increased risks of major postoperative complications for patients on immunosuppressants, with the highest risks observed in those on anti-rejection therapy (aOR: 1.96, 95% CI 1.29-2.98, p = 0.002), combination therapies (aOR: 1.83, 95% CI 1.45-2.3, p < 0.001), and corticosteroids (aOR: 1.58, 95% CI 1.28-1.96, p < 0.001).
conclusionThis study provides the first comprehensive national-level analysis of class-specific immunosuppressant effects on TJA outcomes. Our study revealed that chronic immunosuppressant use significantly increased odds of major postoperative complications in TJA patients, with the highest risks associated with anti-rejection therapies, combination therapies, and corticosteroids. These findings underscore the need for optimized perioperative risk stratification, and tailored management strategies to mitigate adverse outcomes in TJA patients on chronic immunosuppressant therapy. LEVEL OF EVIDENCE III: Retrospective Cohort Study.
Indexed as
Identifiers
41359222What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.